Search | Clinical Trials Finder

Conditions: Hepatitis C
Interventions: rosiglitazone; Drug
Lead sponsor: Brooke Army Medical Center; Federal
Eligibility: 18 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2010
U.S. locations: 1
States / cities: Fort Sam Houston, Texas

Conditions: Hypertension, Insulin Resistance, Metabolic Syndrome
Interventions: Olmesartan medoxomil, Losartan potassium, Atenolol; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 10
States / cities: Birmingham, Alabama • San Diego, California • Miami, Florida + 7 more

Conditions: HIV-Associated Lipodystrophy Syndrome, Insulin Resistance, HIV Infections, Metabolic Syndrome X, Body Weight Changes
Interventions: Rosiglitazone, Recombinant human growth hormone + rosiglitazone; Drug
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 77 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2010
U.S. locations: 4
States / cities: New York, New York

Conditions: Diabetes Mellitus, Type 2
Interventions: iRF System Hepatic Denervation; Device
Lead sponsor: Metavention; Industry
Eligibility: 22 Years to 70 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 8
States / cities: Birmingham, Alabama • Stanford, California • Orlando, Florida + 5 more

Conditions: Obesity, Abdominal, Dyslipidemias, Insulin Resistance, Blood Pressure, Weight Loss
Interventions: Time Restricted Eating, Standard Cardiometabolic Health Diet; Behavioral
Lead sponsor: University of California, Irvine; Other
Eligibility: 22 Years to 75 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Irvine, California

Conditions: Transgender, Gender Identity, Vascular Stiffness, Vascular Inflammation, Insulin Sensitivity, Blood Pressure, Lipid Disorder, Appetitive Behavior
Interventions: No intervention; Other
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 99 Years
Enrollment: 17 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Glucose, High Blood
Interventions: Human Insulin, Finger-actuated, Metered Pump Sprayer; Biological · Device
Lead sponsor: Transdermal Delivery Solutions Corp; Industry
Eligibility: 25 Years to 75 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027
U.S. locations: 1
States / cities: Palm Beach Gardens, Florida

Conditions: Sleep Deprivation
Interventions: Time restricted eating (TRE); Behavioral
Lead sponsor: Pennington Biomedical Research Center; Other
Eligibility: 18 Years to 45 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: Baton Rouge, Louisiana

Conditions: Human Immunodeficiency Virus Infection
Interventions: rice bran arabinoxylan compound (RBAC), Placebo; Dietary Supplement
Lead sponsor: University of Miami; Other
Eligibility: 18 Years and older
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Diabetes Mellitus
Interventions: Oral Anti-diabetes Drugs alone, Basal bolus insulin, Supplemental insulin, Continuous glucose monitoring (CGM); Drug · Device
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 255 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 3
States / cities: Atlanta, Georgia

Conditions: Type 2 Diabetes
Interventions: Continuous Glucose Monitoring (CGM)-based titration algorithm implemented in DiAs; Device
Lead sponsor: University of Virginia; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 2
States / cities: New York, New York • Charlottesville, Virginia

Conditions: HIV Infections, Lipodystrophy, Insulin Resistance
Interventions: Avandia administration for 6-12 weeks; Drug
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 18 Years to 55 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2003
U.S. locations: 1
States / cities: Stony Brook, New York

Conditions: Type 1 Diabetes
Interventions: Acipimox, Placebo; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 25 Years to 59 Years
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: HIV Infections
Interventions: Abacavir sulfate, Amprenavir, Lamivudine; Drug
Lead sponsor: Glaxo Wellcome; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1999
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Insulin Resistance, Cardiovascular Diseases, Heart Diseases, HIV Infections, Hypertriglyceridemia, Hyperlipidemia
Interventions: Acipimox; Drug
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 18 Years to 65 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2006
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Pre Diabetic
Interventions: Fig, Control; Other
Lead sponsor: Clinical Nutrition Research Center, Illinois Institute of Technology; Industry
Eligibility: 30 Years to 50 Years · Female only
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Metabolic Syndrome
Interventions: Indomethacin, Placebo, MRI; Drug · Diagnostic Test
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years to 45 Years
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Obesity, Polycystic Ovary Syndrome, Prehypertension, PreDiabetes, Cardiovascular Risk Factor, Metabolic Syndrome
Interventions: Heat therapy; Behavioral
Lead sponsor: University of Oregon; Other
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Eugene, Oregon

Conditions: HIV Infections, Non-Alcoholic Fatty Liver Disease
Interventions: Semaglutide; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 8
States / cities: Birmingham, Alabama • Aurora, Colorado • Baltimore, Maryland + 5 more

Conditions: Type 2 Diabetes, Insulin Dependent Diabetes
Interventions: Not listed
Lead sponsor: Clinical Nutrition Research Center, Illinois Institute of Technology; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Type 2 Diabetes
Interventions: IcoSema, Insulin glargine; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 485 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 43
States / cities: Birmingham, Alabama • Concord, California • La Jolla, California + 37 more

Conditions: Supplement
Interventions: T+ Supplement, Placebo; Other
Lead sponsor: Florida State University; Other
Eligibility: 18 Years to 35 Years · Male only
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Tallahassee, Florida

Conditions: Human Immunodeficiency Virus (HIV), Vitamin D Deficiency, HIV Infections
Interventions: Vitamin D, Placebo; Drug · Other
Lead sponsor: University Hospitals Cleveland Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Diabetes Mellitus, Type 1
Interventions: Fixed set point, Variable set point; Device
Lead sponsor: Bruce A. Buckingham; Other
Eligibility: 18 Years to 44 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Stanford, California

Search by objective public record fields.

Infergen, Ribavirin & Avandia in Previous Relapsers or Nonresponders to Pegylated Interferon and Ribavirin

A Comparison of the Effect of Olmesartan Medoxomil, Losartan Potassium, and Atenolol on the Ability of Overweight Patients With High Blood Pressure to Respond to Insulin

Growth Hormone and/or Rosiglitazone for HIV-Associated Increased Abdominal Fat and Insulin Resistance

Evaluation of the Integrated Radio Frequency Denervation System to Improve Glycemic Control in Type 2 Diabetic Subjects

Dietary Approaches for Cardiometabolic Health

The Effects of Orchiectomy and Age on Vascular and Metabolic Health in Older Versus Younger Transgender Women

Dose Response Study of Transdermal Human Insulin in Patients

Cardiovascular Risk and Circadian Misalignment in Short Sleepers - Role of Extended Eating Period

The Effect of an Enhanced Rice Bran Nutritional Supplement in HIV

Oral Anti Diabetic Agents in the Hospital

The Effect and Safety of a Novel CGM-Based Titration Algorithm for Basal Insulin in T2DM Participants.

Underlying Abnormalities in Fat and Muscle Leading to Lipodystrophy Syndrome

Effects of Acipimox on Insulin Action, Vascular Function, and Muscle Function in Type 1 Diabetes

A Study of the Effects of Amprenavir, a Protease Inhibitor, on Carbohydrate and Fat Metabolism in HIV-Infected Patients

Acipimox to Improve Hyperlipidemia and Insulin Sensitivity Associated With HIV

How Fig Polyphenols Affect Blood Sugar and Insulin Levels After Eating in Adults at Risk for Diabetes

Human Cerebrovascular Blood Flow and Sex Differences in Metabolic Syndrome

Heat Therapy and Cardiometabolic Health in Obese Women

Study of Semaglutide for Non-Alcoholic Fatty Liver Disease (NAFLD), a Metabolic Syndrome With Insulin Resistance, Increased Hepatic Lipids, and Increased Cardiovascular Disease Risk (The SLIM LIVER Study)

Mathematical Modeling of Blood Sugar and Hormone Responses in Insulin-Dependent Type 2 Diabetes

A Research Study to See How Well New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Levels in People With Type 2 Diabetes (T2D), Compared to Daily Insulin Glargine (COMBINE 4)

Multi-ingredient Supplement for Strength and Power

Study of Vitamin D and Effect on Heart Disease and Insulin Resistance

An Outpatient Study of Automated Blood Glucose Control With an Insulin-Only Bionic Pancreas